相关实验视频
Updated: Jun 8, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.2K
使用持续的葡萄糖监测来控制糖尿病病中的血糖
Vamsidhar Veeranki1, Narayan Prasad2
1Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India.
World journal of diabetes
|November 4, 2024
概括
与传统的HbA1c测试相比,持续血糖监测 (CGM) 为慢性病患者的血糖跟踪提供了一种优越的方法. 这项技术有助于管理血糖控制和降低CKD群体的风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
背景情况:
- 在慢性病 (CKD) 中管理血糖控制是复杂的,特别是在透析或移植后末期病的糖尿病患者中.
- 常规标记物如糖化血红蛋白 (HbA1c) 可能在CKD中由于贫血和功能障碍导致不准确的血糖读数.
研究的目的:
- 审查HbA1c在评估CKD患者血糖控制中的局限性.
- 探索持续血糖监测 (CGM) 的实用性和挑战,作为CKD管理中的替代方案.
主要方法:
- 综合性文献综述,重点研究评估CGM在各种CKD人群 (血液透析,腹腔透析,移植接受者) 中的研究.
- 分析CGM提供实时和追溯血糖测量的能力.
主要成果:
- CGM克服了HbA1c的局限性,提供了更准确的反映CKD的血糖波动.
- 研究证实了CGM在监测血糖趋势和减轻CKD患者低血糖/高血糖风险方面的价值.
- 传感器精度波动是一个挑战,需要进一步研究以获得最佳的临床使用.
结论:
- 在CKD患者中,CGM是管理血糖的宝贵工具,其表现优于传统标记物.
- 建议将CGM整合到临床实践中,以改善患者的治疗结果并减少血糖变化.
- 进一步的研究是必不可少的,以完善CGM的使用,并解决其在CKD群体中的局限性.
相关概念视频
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K

